Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01099631 · ClinicalTrials.gov registry record · Phase 1
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
A Phase 1 study of Liver Cancer and Liver Neoplasms, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT01099631 is a Phase 1 study of Liver Cancer and Liver Neoplasms that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 22 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01099631, a Phase 1 study of Liver Cancer and Liver Neoplasms, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The working hypothesis is that oral administration of an attenuated strain of Salmonella typhimurium is safe and efficacious for patients with unresectable hepatic metastasis from a solid tumor cancer. The primary objective of the study is to determine the MTD of Salmonella typhimurium in the treatment.
Conditions Studied
Interventions
- BIOLOGICAL Salmonella typhimurium
Study Locations (1)
Minnesota
- Edward W. Greeno, MD - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01099631
The ClinicalTrials.gov registry entry for NCT01099631 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which Salmonella typhimurium is the first listed.
NCT01099631 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01099631 about?
NCT01099631 is a clinical study titled "IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread". The working hypothesis is that oral administration of an attenuated strain of Salmonella typhimurium is safe and efficacious for patients with unresectable hepatic metastasis from a solid tumor cancer. The primary objective of the study is to determine the MTD of Salmonella typhimurium in the treatm...
What is the current status of trial NCT01099631?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2010-04. Estimated completion is 2014-06.
What conditions does trial NCT01099631 study?
This clinical trial studies the following conditions: Liver Cancer, Liver Neoplasms, Biliary Cancer, Hepatoma, Cancer of the Liver.
What interventions are being tested in trial NCT01099631?
The interventions under investigation include: Salmonella typhimurium (BIOLOGICAL).
Who is sponsoring clinical trial NCT01099631?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01099631 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RECRUITING · Phase 1
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
ACTIVE NOT RECRUITING · Phase 1
-
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.